SynthesisBMC cancer2023

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.

Javier Cortes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.